- Document Number:
20240424078
- Appl. No:
18/761709
- Application Filed:
July 02, 2024
- نبذة مختصرة :
A method of immunizing a human female subject to decrease the risk of Group B Streptococcus (GBS) disease in an infant born to the subject, by providing a priming dose of a GBS vaccine and, more than thirty days after the priming dose, providing a boosting dose of a GBS vaccine.
- Assignees:
GLAXOSMITHKLINE BIOLOGICALS SA (Rixensart, BE)
- Claim:
1-15. (canceled)
- Claim:
16. A method of decreasing risk of Group B Streptococcus (GBS) disease in an infant born to a human female subject, the method comprising: a) administering a priming dose of a GBS vaccine to the subject; and b) administering a successive GBS vaccine to the subject from no sooner than 24 months to no later than 7 years after administration of the priming dose, wherein the successive GBS vaccine is a boosting dose of a GBS vaccine, wherein the GBS vaccine comprises at least two GBS capsular polysaccharides selected from the group consisting of GBS serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, wherein said at least two GBS capsular polysaccharides are each conjugated to CRM197 carrier protein, wherein the GBS vaccine does not comprise an alpha-like protein 3 (ALP3) polypeptide, and wherein the priming dose and the boosting dose each elicit in the subject IgG antibodies specific for a disease-causing GBS serotype, provided that at least a portion of the IgG antibodies specific for the disease-causing GBS serotype is transferred across the subject's placenta to the infant and is present in the infant at birth, thereby decreasing risk of GBS disease in the infant.
- Claim:
17. The method of claim 16, wherein risk of GBS Early Onset Disease (EOD) is reduced in the infant born to the subject after administration of the boosting dose, compared to risk of GBS EOD in the absence of the boosting dose.
- Claim:
18. The method of claim 16, wherein risk of GBS Late Onset Disease (LOD) is reduced in the infant born to the subject after administration of the boosting dose, compared to risk of GBS LOD in the absence of the boosting dose.
- Claim:
19. The method of claim 16, wherein both the priming dose and the boosting dose comprise at least two GBS capsular polysaccharides selected from the group consisting of GBS serotypes Ia, Ib, and III and elicit IgG antibodies specific for GBS serotypes Ia, Ib, and III.
- Claim:
20. The method of claim 16, wherein the priming dose is administered to the subject when the subject is not pregnant, and the boosting dose is administered to the subject when the subject is pregnant.
- Claim:
21. A method of providing functional serotype-specific Group B Streptococcus (GBS) IgG antibodies to a human infant, the method comprising: a) administering a priming dose of a GBS vaccine to a human female subject; and b) administering a successive GBS vaccine to the subject from no sooner than 24 months to no later than 7 years after administration of the priming dose, wherein the successive GBS vaccine is a boosting dose of a GBS vaccine, wherein the GBS vaccine comprises at least two GBS capsular polysaccharides selected from the group consisting of GBS serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, wherein said at least two GBS capsular polysaccharides are each conjugated to CRM197 carrier protein, wherein the GBS vaccine does not comprise an alpha-like protein 3 (ALP3) polypeptide, wherein the priming dose and the boosting dose each elicit in the subject IgG antibodies specific for a disease-causing GBS serotype, and wherein at least a portion of the IgG antibodies are transferred across the subject's placenta to the infant prior to birth and are present in the infant at birth.
- Claim:
22. The method of claim 16, wherein the boosting dose is administered to the subject at least four years after the priming dose.
- Claim:
23. The method of claim 16, wherein the IgG antibodies specific for the disease-causing GBS serotype is present at ≥1 μg/ml in the infant at birth.
- Claim:
24. The method of claim 16, wherein (a) the priming dose comprises an adjuvant; (b) the boosting dose comprises an adjuvant; (c) both of the priming dose and the boosting dose comprise an adjuvant; or (d) the priming dose comprises an adjuvant and the boosting dose does not comprise an adjuvant.
- Current International Class:
61; 61; 61
- الرقم المعرف:
edspap.20240424078
Processing Request
No Comments.